Previous Article | Next Article ![]()
Journal of Virology, November 2006, p. 10600-10614, Vol. 80, No. 21
0022-538X/06/$08.00+0 doi:10.1128/JVI.00455-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
,
Megan E. Schroeder,2
David P. Giedroc,3 and
Julian L. Leibowitz1,2*
Department of Microbial and Molecular Pathogenesis, Texas A&M University System College of Medicine, College Station, Texas 77843-1114,1 Department of Veterinary Pathobiology, Texas A&M University, College Station, Texas 77843-4467,2 Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas 77843-21283
Received 3 March 2006/ Accepted 9 August 2006
|
|
|---|
|
|
|---|
Coronavirus-infected cells contain 6 to 11 distinct RNA species (18). The intracellular RNAs form a nested set with common 3' ends, with the longest RNA being the intracellular counterpart of the virion RNA (1). For mouse hepatitis virus (MHV), the 21-kb-long gene 1 contains two open reading frames (ORF1a and ORF1b); a 1 ribosomal frameshift during translation (2) results in the synthesis of a putative 7,178-amino-acid ORF1ab polyprotein. The resulting 740-kDa polypeptide contains a conserved array of functional domains: papain-like cysteine protease(s), ADP-ribose-1"-monophosphate-processing enzyme (X domain), a two-ß-barrel-fold (picornavirus 3C-like) main protease, RNA-dependent RNA polymerase, zinc-binding domain-containing helicase, putative exoribonuclease, endoribonuclease, and ribose-2'-O-methyltransferase domains (23).
The coronaviruses have been classified into three subgroups, termed group 1, group 2, and group 3, based on serologic relatedness, genetic organization, and sequence similarity (30). SCoV was originally placed in its own unique group by primary genomic analysis (27). Although somewhat controversial, more recent phylogenetic studies using a variety of software tools and comparing a more extensive set of amino acid sequences than those used in the original analysis (ORF1a, ORF1b, spike [S], envelope [E], membrane [M], and nucleocapsid [N]) revealed that SCoV is best placed as an early branch of the group 2 coronaviruses (9, 30, 38). This group contains MHV (one of the best-characterized coronaviruses), human respiratory coronavirus (HCoV-OC43), and bovine coronavirus (BCoV), among others.
Coronavirus untranslated regions (UTRs) contain cis-acting sequences and structures known to play essential roles in RNA synthesis, gene expression, and virion assembly (6, 10, 16). Although coronaviruses of the same species recombine with high frequency (22), only a few studies have examined the ability of different coronaviruses to recombine (10, 13). Based on the conservation of secondary structures (a bulged stem-loop and an adjacent pseudoknot) in the 3' untranslated regions (3'UTRs) of all group 2 coronaviruses, functional studies have shown that the MHV 3'UTR can be functionally replaced with the 3'UTRs from BCoV (13) and SCoV (10). Previously, others have partially characterized four stem-loop structures (I to IV) in the BCoV 5'UTR (5, 24, 25). Many of the features of this secondary structural model of the BCoV 5'UTR are supported by enzymatic structure probing and defective interfering (DI) RNA replication experiments. Somewhat surprisingly, stem-loops I and II do not have precise higher-order counterparts in the group 1 and group 3 coronaviruses. In this report, we present an alternative consensus secondary structural model of the coronavirus 5'UTRs (Fig. 1A) (17, 21). The model was developed by covariation analysis of a multiple sequence alignment of the 5' 140 nucleotides (nt) of the 5'UTRs from nine coronaviruses from all three subgroups and is supported by a variety of RNA secondary structure prediction algorithms (7, 12, 26, 40) as well as nuclear magnetic resonance (NMR) analyses and genetic studies (P. Liu et al., unpublished data; L. Li and D. Giedroc, unpublished data). This model predicts three stem-loops, SL1, SL2, and SL4, that are structurally conserved among the group 1 and group 2 coronaviruses, including SCoV. Putative SL2 contains a (C/U)UUG(U/C) pentaloop sequence that is the most highly conserved contiguous run of nucleotides in the entire 5'UTR outside of the core transcriptional regulatory sequence (TRS), and covariation analysis reveals that this loop is always stacked on a 5-bp helix (Fig. 1B). SCoV is predicted to have an additional putative stem-loop structure (SL3) that contains both the SCoV TRS (ACGAAC) (15, 32) and MHV TRS (UCUAAAC) core sequences (CSs) (3, 28). Although 5'UTRs of the group 2 coronaviruses have a high degree of sequence similarity and are predicted to have similar secondary structures, to date, no study has investigated the ability of various 5'UTRs or portions of the UTRs from different species of coronaviruses to function in the context of a heterologous coronavirus genome. Studies on the ability of the SCoV 5'UTR to function in the background of the MHV genome are likely to be informative regarding the suggested phylogenetic relationship between these two viruses (30) and may indicate the potential for recombination between a significant human pathogen, SCoV, and related animal coronaviruses.
![]() View larger version (32K): [in a new window] |
FIG. 1. Predicted secondary structures within the 140-nt 5'UTR of the MHV and SCoV genomes (see the text for details). Previously described predicted stem-loops 1 (SL1) (boldface and italic type), 2 (SL2) (large font and italics), and 4 (SL4) (large font) in the 5'UTRs are noted (17, 21). MHV leader TRS CS (boldface, underlined type) is contained within the linear sequence between SL2 and SL4. However, the SCoV leader TRS CS (boldface, underlined type) is contained within stem-loop 3 (SL3) (boldface type). The AUGs shown represent the start codons of nsp1 in the MHV (nt 210 to 212) and SCoV (nt 265 to 267) genomes. indicates noncanonical base pairings. (B) SL2 sequence alignment of group 2 coronaviruses. The stem portion of SL2 is underlined; the U-turn motif is italicized; * indicates absolutely conserved nucleotides. SL2 sequences of MHV (GenBank accession no. NC_001846), SCoV (accession no. AY278741), BCoV (accession no. NC_003045), HCoV-OC43 (accession no. NC_005147), HCoV-HKU1 (accession no. NC_006577), HCoV-NL63 (accession no. NC_005831), HCoV-229E (accession no. NC_002645), TGEV (accession no. NC_002306), and IBV (accession no. NC_001451) are relative to the corresponding viral genomes in GenBank.
|
|
|
|---|
Assembly of a full-length MHV-A59 infectious construct. The reverse genetic system for MHV-A59 used in this study was initially described by Yount et al. (37). cDNAs representing the entire MHV-A59 genome with either the wild-type sequence or the MHV/SCoV chimeric sequences were constructed by ligation of the A (or G) fragments to fragments (A)B to G(F) as described previously (37). Chimeric and wild-type MHV genomes were transcribed and electroporated into cells as previously described (37). Cultures were observed for up to 72 h for the development of a cytopathic effect (CPE) (cell fusion) and harvested by freezing at 70°C. Cultures that did not develop a CPE were blind passaged three times through DBT cells in a further attempt to recover infectious virus. At least three independent experiments, including at least one experiment in which electroporated cells were incubated at 34°C and 40°C, were performed before a mutant genome was considered nonviable.
Plasmid constructions. The primers used in this study are listed in Table 1. The A plasmid of the MHV reverse genetic system described previously by Yount et al. (37) was utilized as a basis for constructing a fusion of the SCoV 5'UTR to the MHV gene 1 coding sequence. The strategy employed to construct this fusion exploited "no see'm" technology to eliminate a BsmBI restriction site engineered into the end of DNA fragments by PCR (37). Briefly, the entire SCoV 5'UTR was amplified from purified SCoV RNA (Urbani strain) (27), obtained from the Center for Disease Control and Prevention (CDC), by reverse transcription (RT)-PCR using primers that contained additional BsmBI sites (S 5'UTR swap oligonucleotides 3 and 7). The resultant RT-PCR product was TA cloned into the pGEM-T vector (Promega) to produce plasmid 0A-1, maintaining the BmsBI sites. Plasmid 0A-2 was produced by subcloning a BamHI fragment from the A plasmid of the MHV reverse genetic system into the PCR-XL-TOPO vector (Invitrogen). This BamHI fragment contained a small portion of the A plasmid backbone, a T7 promoter, and the first 252 nt of the MHV genome, extending into the MHV gene 1 coding region. The MHV 5'UTR was removed from plasmid 0A-2 by inverse PCR with Pfx DNA polymerase (Invitrogen) using primers that contained BsmBI sites (S 5'UTR swap oligonucleotides 5 and 6), followed by self-ligation to produce plasmid 0A-3. The SCoV 5'UTR was excised from plasmid 0A-1 by BsmBI digestion and ligated with BsmBI-digested plasmid 0A-3 to produce plasmid 7074. This ligation eliminated the BsmBI sites and precisely fused the SCoV 5'UTR to the MHV gene 1 coding sequence. After sequencing to verify the construction, a restriction fragment exchange was performed to replace the 550-bp BamHI fragment in MHV plasmid A with the 620-bp BamHI fragment containing a T7 promoter plus the SCoV 5'UTR fused to 252 nt of the MHV gene 1 coding sequence. This chimeric plasmid was called pHK0A and could be used in the MHV reverse genetic system in place of plasmid A. A similar strategy was used to replace the MHV 3'UTR with the SCoV 3'UTR (27) in the MHV reverse genetic system G plasmid. The SCoV 3'UTR and 15 nt of the poly(A) tail were amplified from purified SCoV RNA (27) by RT-PCR using primers that contained BsmBI sites (oligonucleotides 1 and 2), which could subsequently be eliminated during ligation, and cloned (plasmid 0G-1). In plasmid 0G-1, the MHV-A59 sequences between an ApaI site at position 30072 (relative to the MHV-A59 genome) (GenBank accession no. NC_001846) (39) and a PacI site inserted just downstream of the poly(A) tail were derived from plasmid B36 (14). Inverse PCR (oligonucleotides 3 and 4) was utilized to produce plasmid 0G-2, replacing the MHV 3'UTR with two BsmBI sites separated by a small spacer sequence. After digestion by the BsmBI restriction enzyme, the plasmid 0G-1 fragment containing the SCoV 3'UTR was ligated into BsmBI-digested plasmid 0G-2 to eliminate the BsmBI sites, producing plasmid 0G-3. This plasmid contained a fusion of the last 969 nt of the N coding sequence to the SCoV 3'UTR. This was then transferred to the MHV genetic system G plasmid by restriction fragment exchange to produce a plasmid called pMF0G.
|
View this table: [in a new window] |
TABLE 1. Primers used in this study
|
![]() View larger version (59K): [in a new window] |
FIG. 2. Schematic diagram depicting the major constructs used throughout this study. Both the names of the recombinant genomes and plasmids (in parentheses) used to construct these chimeric genomes are shown. The predicted stem-loop structures in the 5' 140 nt of MHV and SCoV are indicated in the schematic. The positions of the first and last nucleotides are indicated below the boxes depicting the predicted stem-loops. The complete 5'UTR and 3'UTR of SCoV are represented by open rectangles. Single-stranded regions derived from SCoV and MHV are indicated by the thick and thin lines, respectively. The sequences of the 5'UTRs of MHV, SCoV, and each of the chimeric genomes used in this study are shown. SCoV-derived nucleotides are underlined. Boldface type indicates a predicted single-stranded region between the first nucleotide and the predicted 3' end of SL4. Italicized sequenced are predicted to fold into the stem-loop structures as labeled above the italicized sequences. Bold dashes indicate transitions from predicted stem-loops to single-stranded regions. Sequences 3' to SL4 are shown in lightface type and are not encompassed by our structural model.
|
|
View this table: [in a new window] |
TABLE 2. Plasmids used in this study
|
Growth curves. DBT cells were grown in 96-well plates, and replicate wells were infected at a multiplicity of infection (MOI) of 3 with mutant or wild-type MHV-A59 1000 virus. After washing away the inocula, cultures were incubated until 0, 4, 8, 12, 16, and 24 h postinfection, when they were frozen at 70°C. Triplicate samples were obtained at all time points. Virus production was quantitated by plaque assay on L2 cell monolayers.
Metabolic labeling. DBT cells (2.25 x 105 cells/well) were seeded into 24-well plates and incubated at 37°C for 15 h to reach approximately 2.5 x 105 cells. The DBT cells were infected at an MOI of 1 (2.5 x 105 PFU) or mock infected, further incubated for 6 h, washed two times with phosphate-free DMEM, fed with DMEM supplemented with 2% dialyzed calf serum and 10 µg/ml of actinomycin D, and incubated at 37°C for 15 min. At the end of 15 min, the medium was replaced with phosphate-free medium containing 10 µg/ml actinomycin D, 2% dialyzed serum, and 200 µCi/ml 32PO4 and incubated at 37°C for 5.5 h, by which time 90% of the cells infected with wild-type MHV-A59 1000 had formed syncytial giant cells. The labeled cultures were washed twice with cold phosphate-buffered saline, and RNA was extracted using an RNeasy Mini kit (QIAGEN). The amount of RNA in each sample was measured using the RediPlate 96 RiboGreen RNA quantitation kit (Invitrogen). Equal amounts of radiolabeled viral RNA (10 µg) were denatured in formaldehyde gel loading buffer containing ethidium bromide (20 µg/ml) at 65°C for 15 min and then electrophoresed in a 1% formaldehyde-agarose gel at 100 V for 5 h. Following electrophoresis, the gel was illuminated with UV light, the image was captured with a FluorChem 8900 (AlphaInotech) imaging system, and the relative amount of 18S rRNA bands was determined by densitometry. The gel was soaked in 70% methanol for 30 min, dried over a vacuum, and exposed to X-ray film. The amount of the individual subgenomic RNAs (sgRNAs) relative to genome-sized RNA (gRNA) and the relative amount of radiolabeled RNA in each sample were determined by exposing the dried gel to a Molecular Dynamics PhosphorImager equipped with Storm 8.2 software. The amount of 18S rRNA in each sample was used to normalize the PhosphorImager signals to account for small differences in the total amounts of RNA loaded per sample.
Detection of gRNA and sgmRNA. A series of nested RT-PCR assays was performed to analyze RNAs produced by nonviable chimeric genomes. Chimeric genomes or wild-type MHV-A59 1000 RNA was electroporated into BHK-R cells, and total RNAs were extracted at 8 and 24 h postelectroporation (p.e.). In order to determine if the input RNAs, plus any replicated genome RNA, were present in the electroporated cells, the extracted RNAs were primed for reverse transcription by 7059 antisense oligonucleotide 8, followed by PCR using SCoV or MHV 5' 1-20 (+) primers and 7059 () oligonucleotide 8. The RNA species present in cells electroporated with these chimeric genomes were characterized using nested RT-PCR methods described previously (16, 17, 21). For analyzing the synthesis of minus-sense gRNA by the chimeric viruses, the extracted RNAs were primed for reverse transcription by oligonucleotide A59(+) 14639-14658 and followed by the first PCR using oligonucleotide A59(+) 14639-14658 and oligonucleotide A59() 16596-16577. The resultant PCR products were further amplified by nested PCR using oligonucleotide A59(+) 16038-16059 and oligonucleotide A59() 16596-16577. Parallel reactions (without RT) in which reverse transcriptase was omitted from the cDNA step were always performed to ensure that the PCRs did not detect residual DNA transcription templates that entered the cells during electroporation. To detect plus- or minus-sense subgenomic mRNA7 (sgmRNA7), the extracted RNAs were primed for reverse transcription by antisense primer 7065 to detect minus-sense sgmRNA7 and by SCoV (GenBank accession no. AY278741) or MHV 5' 1-20 sense primers to detect minus-sense sgmRNA7, respectively. The resultant cDNAs were used as templates for the first PCR using SCoV or MHV 5' 1-20 sense primers and the 7065 antisense primer. The first PCR products were further amplified by nested PCR using SCoV or MHV 5' 1-20 sense primers and the N antisense primer, and the nested PCR products were displayed by gel electrophoresis.
|
|
|---|
In contrast to SL2, the predicted structures of SL1 and SL4 differ in detail between MHV and SCoV. MHV SL1 has a longer hairpin loop and has two consecutive pyrimidine-pyrimidine mismatches in the stem that are not predicted to be present in SCoV SL1. The predicted MHV SL4 stem contains two internal loops not present in the SCoV SL4 stem. The SCoV 140-nt sequence is predicted to contain a fourth putative stem-loop, named SL3, spanning the SCoV TRS 5'-flanking sequence (5'FS) and CSs. Consistent with our data, van den Born et al. previously predicted that the SCoV TRS CS was contained in the loop portion of a stem-loop structure (33). The counterpart MHV TRS sequence is located between SL2 and SL4 but is predicted to be single stranded or weakly folded at 25°C. The predicted single-stranded region between SCoV SL1 and SL2 was longer (8 nt) than the corresponding region in MHV (1 nt). The SCoV sequence region between the putative SL4 and the start codon of nsp1 (nt 131 to 264) is 65 nt longer than its MHV counterpart (nt 141 to 209), and no significant similarity was found between the two RNA sequences in this region. ViennaRNA 1.5 predicted that this SCoV sequence region forms four stem-loop structures but that its MHV counterpart forms just two stem-loop structures.
The SCoV 5'UTR cannot functionally replace the MHV 5'UTR. An examination of the sequences contained in the SCoV 5'UTR SL3 revealed that in addition to the SCoV TRS CS (ACGAAC [nt 67 to 72]), this structure also contained an overlapping MHV TRS CS (UCUAAAC [nt 62 to 67]) (Fig. 1). This led us to investigate whether the SCoV 5'UTR could functionally replace its MHV counterpart. In the reverse genetic system for MHV-A59 described previously by Yount et al. (37), plasmid A contains the 5'UTR plus an additional 4,672 nt of the ORF1a coding sequence. As described in Materials and Methods, we generated a modified plasmid A in which the entire MHV 5'UTR was precisely replaced by the SCoV 5'UTR (pHK0A) (Table 2 and Fig. 2). The chimeric cDNA contained in this plasmid was excised and ligated to cloned cDNAs B to G (37) and transcribed in vitro to generate chimeric MHV-A59 genome RNAs in which the SCoV 5'UTR had replaced the corresponding MHV sequences (MHV/SCoV-5'UTR). Three attempts to recover infectious virus after electroporation into MHV-permissive BHK-R cells were unsuccessful, including one attempt in which replicate electroporated cultures were incubated at 34°C and 40°C. To confirm that these chimeric genomes were nonviable, the electroporated cell cultures were frozen at 70°C to release cell-associated virus and blind passaged three times on DBT cells without developing cytopathic effects. Lysates from the third blind passage were subjected to plaque assay using L2 cells. No plaques were observed in all three independent experiments. Thus, we concluded that the MHV/SCoV-5' UTR chimeric genome was nonviable (Fig. 3).
![]() View larger version (102K): [in a new window] |
FIG. 3. Morphologies of plaques formed by MHV and SCoV chimeric genomes. Cultures of BHK-R cells were electroporated with MHV/SCoV chimeric or MHV-A59 full-length transcripts and seeded onto DBT cells in 75-cm2 flasks. If a genome produced viable virus progeny, the progeny was plaque purified and amplified once in DBT cells. The plaques shown are wild-type MHV-A59 1000 virus (A), MHV/SCoV-SL1 (E), MHV/SCoV-SL2 (F), MHV/SCoV-SL4 (H), and MHV/SCoV-3'UTR (C) chimeric viruses. Nonviable chimeric genomes did not form any visible plaque (B, D, G, I, J, and K).
|
SCoV 5'UTR SL1, SL2, and SL4 were functionally exchangeable with their MHV counterparts. We next determined whether individual predicted stem-loop structures in the SCoV 5'UTR could functionally replace their MHV counterparts. The following MHV/SCoV chimeric genomes were generated as described in Materials and Methods (Table 2 and Fig. 2): (i) A59/SCoV-SL1 (MHV SL1 was replaced with SCoV SL1 using pHK5A), (ii) A59/SCoV-SL2 (MHV SL2 was replaced with SCoV SL2 using pHK18A), (iii) A59/SCoV-SL3 (MHV TRS CS and 8 nt of the 5'FS were replaced with SCoV SL3 using pHK12A), (iv) A59/SCoV-SL4 (MHV SL4 was replaced with SCoV SL4 using pHK8A), (v) A59/SCoV-b/w SL4&AUG (the MHV sequence region between SL4 and the start codon [AUG] of nsp1 was replaced with its SCoV counterpart using pHK11A), and (vi) MHV/SCoV-3'UTR (MHV 3'UTR was replaced with the SCoV 3'UTR using pMF1G). As a negative control, A59/nsp12-FS was generated using pLP1F, a plasmid that contained a cDNA construct harboring a frameshift mutation in the RdRp domain (nsp12) that should abrogate the translation of downstream nsp13 to nsp16. Cultures electroporated with A59/SCoV-SL1, A59/SCoV-SL2, A59/SCoV-SL4, and A59/SCoV-3'UTR chimeric genomes developed a CPE after 24 to 48 h. Viable virus was recovered from the medium, plaque purified, and expanded in DBT cells (Fig. 3). Sequencing analyses confirmed that there were no additional mutations in the 3'UTRs and 5'UTRs of the recovered viruses. The cultures electroporated with A59/SCoV-SL3 and A59/SCoV-b/w SL4&AUG chimeric genomes and the A59/nsp12-FS mutant genome failed to develop CPE. To confirm that these viral genomes were nonviable, the electroporated cell cultures were frozen at 70°C to release cell-associated virus and blind passaged three times on DBT cells. Lysates from the third blind passage were subjected to plaque assay using L2 cells. No plaques were observed in three independent experiments for each of these viruses. Thus, the A59/SCoV-SL3 and A59/SCoV-b/w SL4&AUG chimeric genomes and the A59/nsp12-FS mutant genome were judged to be nonviable (Fig. 3).
Phenotypic properties of the MHV/SCoV chimeric viruses. Plaque size and growth kinetics of the recovered chimeric viruses were compared to those of parental MHV-A59 1000. As shown in Fig. 3, the MHV/SCoV chimeric viruses made smaller plaques than the parental MHV-A59 1000 virus. Average plaque sizes of A59/SCoV-SL1, A59/SCoV-SL2, A59/SCoV-SL4, and A59/SCoV-3'UTR chimeric viruses were 1.2 (±0.07), 1.8 (±0.09), 1.1 (±0.04), and 1.4 (±0.07) mm in diameter, respectively (Fig. 4). These sizes corresponded to 39% (P < 0.05) to 64% (P < 0.05) of the average plaque size of MHV-A59 1000, which is 2.8 (±0.07) mm in diameter. A59/SCoV-SL1, A59/SCoV-SL4, and A59/SCoV-3'UTR chimeric viruses grew to lower titers, had significantly delayed growth kinetics relative to those of MHV-A59 1000, and achieved maximal titers 15- to 40-fold less than those achieved by the parental MHV-A59 1000 virus (Fig. 5). However, A59/SCoV-SL2 grew almost as well as the parental virus, achieving a titer only fourfold lower than that of MHV-A59 1000 (Fig. 5).
![]() View larger version (19K): [in a new window] |
FIG. 4. Average plaque sizes of wild-type MHV-A59 1000 and MHV/SCoV-SL1, MHV/SCoV-SL2, MHV/SCoV-SL4, and MHV/SCoV-3'UTR chimeric viruses. The middle bar in each column indicates the mean plaque size of the corresponding virus.
|
![]() View larger version (29K): [in a new window] |
FIG. 5. One-step growth kinetics for wild-type MHV-A59 1000 and MHV/SCoV-SL1 (A), MHV/SCoV-SL2 (B), MHV/SCoV-SL4 (C), and MHV/SCoV-3'UTR (D) chimeric viruses. Triplicate DBT cell cultures in a 96-well plate were infected at an MOI of 3 and harvested at the designated hours postinfection, and viral titers were determined by plaque assay.
|
![]() View larger version (66K): [in a new window] |
FIG. 6. RNA synthesis in cells infected with MHV/SCoV chimeric viruses. Cells were either mock infected or infected with MHV/SCoV-SL1, MHV/SCoV-SL2, MHV/SCoV-SL4, MHV/SCoV-3'UTR, or MHV-A59 1000, and viral RNAs were metabolically labeled as described in Materials and Methods. The labeled viral RNAs were resolved by formaldehyde agarose gel electrophoresis and visualized by autoradiography. Brightness and contrast have been adjusted to enhance the visibility of the bands of the MHV/SCoV chimeric viruses using Adobe Photoshop 6.0. Arrows indicate the positions of bands of virus-specific RNA1 to RNA7.
|
|
View this table: [in a new window] |
TABLE 3. Relative molar amounts of virus-specific RNAs synthesized in cells infected with MHV/SCoV chimeric viruses
|
|
View this table: [in a new window] |
TABLE 4. Characterization of RNA species produced by nonviable MHV/SCoV chimeric genomes
|
![]() View larger version (51K): [in a new window] |
FIG. 7. Nested RT-PCR assays for minus-sense gRNA and sgmRNA7. (A) Schematic drawing of the assay used to detect minus-sense () gRNA and the relative locations of the primers within the genome. (B) RT-PCR of RNAs extracted from MHV-A59 1000 (WT) and nonviable MHV/SCoV chimeric genome-electroporated cells at 8 and 24 h p.e. The arrow indicates the specifically amplified fragment from minus-sense gRNA. W/RT and W/O RT indicate products of nested RT-PCR (left) and the corresponding no-RT control reactions (right), respectively. (C) Schematic representation of the RT-nested PCR strategy and primers used to detect minus- and plus-sense sgmRNA7s. (D) Representative nested RT-PCR for minus- and plus-sense sgmRNA7s. The arrow indicates the specifically amplified sgmRNA7 fragment. The relative sizes of the leader sequences in sgmRNA7 and the body of sgmRNA7 are not to scale. The sizes of the marker DNAs in base pairs are shown to the right of electropherograms. The amplified products corresponding to minus-sense sgmRNA7 are shown in lanes 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19. Products corresponding to plus-sense sgmRNA7 are shown in lanes 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20. The position of each primer in the MHV-A59 genome (GenBank accession no. NC_001846) is given in parentheses as part of the primer name. Primer sequences are listed in Table 1. A 1-kbp ladder was used as a molecular size marker.
|
|
|
|---|
Our model differs from prior models of coronavirus 5'UTRs in one important respect. The BCoV model referenced above predicts that the leader TRS CS will be in the loop portion of stem-loop II (5). Similarly, van den Born et al. (33) predicted that in addition to BCoV, other coronaviruses, including MHV, will fold such that the TRS is in the loop portion of a stem-loop structure. In our model, the MHV TRS is unstructured or is contained in a weakly stable stem-loop, SL3 (Fig. 1). mfold 3.1 (http://www.bioinfo.rpi.edu/applications/mfold/old/rna/form1.cgi) generates four secondary structures for the MHV 5' 140 nt. These four structures have free energies of between 33.6 kcal/mol and 32.3 kcal/mol. Two of the four structures (with free energies of 33.4 and 32.8 kcal/mol) position the TRS sequence in the loop portion of a stem-loop. Our secondary structure model corresponds to an mfold structure with a free energy of 32.3 kcal/mol, only slightly less stable than the two structures putting the TRS into a hairpin loop. However, if folding is constrained to take into account the covariation that strongly predicts the existence of SL2 (Fig. 1B), our model is the most stable structure generated by mfold. None of the data rule out the possibility that the secondary structures that we propose for the 5'UTR are in equilibrium with additional structures similar to those proposed previously by van den Born et al. (33) and Chang et al. (5).
We show here that the SCoV 5'UTR cannot functionally replace the MHV 5'UTR, but we confirm data from a previous study where functional replacement of the MHV 3'UTR by the SCoV 3'UTR was observed in a recombinant virus generated by targeted RNA recombination (10). Although there is little sequence identity between the MHV and SCoV 3'UTRs, both 3'UTRs can be folded into similar secondary structures that contain stem-loop and pseudoknot elements characteristic of group 2 coronaviruses (10). However, the full MHV and SCoV 5'UTRs are significantly different in terms of sequences and predicted secondary structures. The SCoV 5'UTR sequence is 55 nt longer than the MHV 5'UTR. Relative to the MHV counterpart, the region downstream of the putative SL4 in the SCoV 5'UTR was expanded to 65 nt in our secondary structure model. This region of the SCoV 5'UTR from 131 to 264 nt is predicted to fold quite differently than the corresponding region of the MHV 5'UTR (nt 141 to 209) and contains two additional stem-loops relative to its MHV counterpart (data not shown). Considering the 5'-most 140-nt sequences of the MHV and SCoV 5'UTRs, which are predicted to fold quite similarly, the SCoV sequence region is predicted to contain an additional stem-loop, called SL3, that is absent from its MHV counterpart. Any or all of these differences in the sequences and secondary structures might contribute to the nonexchangeability of the SCoV 5'UTR for its MHV counterpart.
In the reverse genetic studies reported here, we demonstrate that sequences containing the predicted SCoV SL1, SL2, and SL4 structures can functionally replace their MHV counterparts. The predicted MHV SL1 structure contains two consecutive noncanonical pyrimidine-pyrimidine base pairs in the stem that are not apparent in the predicted SCoV SL1 structure. The SCoV SL1 substitution produced spacing with 2 nt between the predicted MHV SL1 and SL2. The predicted MHV and SCoV SL2 structures both contain identical U-turn motifs in the loop (CUUGU). This U-turn motif is associated with a sharp turn in the phosphate backbone between U0 and N+1 (11). Moreover, both stems of the MHV and SCoV SL2s were identical except for one base pair at the base of the stem. As the MHV and SCoV SL4s contained potential homologs of the BCoV stem-loop III (24), both ViennaRNA 1.5 and Zuker mfold algorithms predict approximately the same secondary structure in the 5'-most 80- to 140-nt sequence regions of MHV, SCoV, and BCoV, with SL4 and stem-loop III structures conserved in all of these viruses and, in fact, in all coronaviruses (24). Overall, these slight differences in the predicted secondary structural configurations of MHV and SCoV stem-loops did not affect viral viability, but they may have contributed to the reduced viral replication efficiency.
In contrast, the MHV sequence region spanning the TRS CS, 6 nt of 5'FS, and 2 nt of 3'FS could not be functionally replaced by its SCoV counterpart, SL3 (chimeric genome A59/SCoV-SL3). Although the SCoV sequence region contains both the MHV and SCoV TRS CSs, the ViennaRNA 1.5 algorithm predicts that the SCoV sequence TRS region forms a stem-loop structure (SL3), while its MHV counterpart adopts an unpaired structure or one that is predicted to be weakly folded at 25°C. NMR and thermal denaturation experiments using an SCoV RNA encompassing SL2 and SL3 (nt 42 to 72) support the presence of a double-hairpin structure in SCoV (Li and Giedroc, unpublished). This structural difference might contribute to the functional nonexchangeability of TRS sequence regions. Similarly, the SCoV sequence region between SL4 and the start codon of nsp1 is also different in both sequence and secondary structure from its MHV counterpart, which might consequently contribute to the nonviability of the A59/SCoV-b/w SL4&AUG chimeric genome.
An attempt to generate a viable A59/SCoV-5'UTR chimeric genome led to the generation of the A59/SCoV-5'UTR/MHV-TRS chimeric genome, a construct that contains the correct MHV leader TRS. However, the resultant chimeric genome was also nonviable and failed to produce minus- or plus-sense sgmRNA7s. Based on these results, the inability of the SCoV 5'UTR to replace the MHV 5'UTR was not a single consequence of a mismatch of the leader TRS with downstream intergenic TRS sequences. Thus, other differences in sequences or secondary structures, especially the difference in sequences between SL4 and the start codon of nsp1, likely contribute to the observed defects in genome replication and subgenomic RNA synthesis.
Minus-sense gRNA was synthesized in the cells electroporated with A59/SCoV-5'UTR/MHV-TRS and A59/SCoV-SL3 chimeric genomes but not in cells electroporated with the A59/SCoV-5'UTR chimera. It was impossible to determine if electroporated cultures containing minus-sense gRNA but not sgmRNA also synthesized a plus-sense genome. Input genome RNA persisted at easily detectable levels in cells electroporated with a genome unable to direct the synthesis of RNA replicase genes (A59/nsp12-FS, a frameshift mutant expected to abrogate the expression of proteins required for RNA replication) until 24 h p.e., a time when cell fusion was apparent in cultures electroporated with MHV-A59 1000 (data not shown). Real-time RT-PCR assays could not detect a quantitative difference in the amounts of plus-sense gRNAs present in cells electroporated with MHV-A59 1000, A59/nsp12-FS, and the nonviable chimeric genomes at 8 h p.e. At 24 h p.e., the amount of plus-sense gRNA present in cells electroporated with MHV-A59 1000 was significantly greater than that present in cells electroporated with A59/nsp12-FS, A59/SCoV-5'UTR/MHV-TRS, or A59/SCoV-SL3 genomes (data not shown). We concluded that the genome RNAs detected in cells electroporated with nonviable chimeras represented electroporated RNA genomes rather than replicated molecules, since they were found in amounts similar to those for the A59/nsp12-FS genome at 8 and 24 h p.e. Thus, in the absence of subgenomic RNA synthesis and cell fusion, it was impossible to determine if plus-sense gRNA synthesis was directed by the nonviable chimeric genomes, because the persistence of the electroporated RNAs would obscure low levels of genome replication.
The nonviable chimeric genomes (A59/SCoV-5'UTR, A59/SCoV-5'UTR/MHV-TRS, and A59/SCoV-SL3) produced neither minus- nor plus-sense sgmRNA7. Thus, the replacement of the entire MHV 5'UTR with the complete SCoV 5'UTR resulted in a genome that failed to synthesize any viral RNA species. Replacement of the SCoV TRS CS with the MHV TRS CS plus 5 nt of 5'FS and 4 nt of 3'FS in the SCoV 5'UTR background allowed the synthesis of minus-sense gRNA but not sgmRNA7s of either sense. In addition, the insertion of the SCoV region spanning the TRS CS and 5'FS 9 nt in place of the corresponding MHV sequences in the MHV 5'UTR background did not disrupt the synthesis of minus-sense gRNA. A possible explanation for the synthesis of this RNA species in cells electroporated with these nonviable chimeric genomes can be found in the three-step working model for coronavirus mRNA transcription described previously (41), consisting of 5'-to-3' complex formation, base-pairing scanning, and template switching. The A59/SCoV-5'UTR chimeric genome might be blocked in the first step, 5'-to-3' complex formation. Both the MHV N protein and the polypyrimidine tract binding (PTB) protein bind to the MHV leader TRS region (20, 35). These proteins might not efficiently bind to the leader MHV TRS CS in the SCoV 5'UTR background, or poor complementarity of sequences flanking the MHV TRS CS may preclude the template jumping step needed for sgmRNA synthesis (29). It has been hypothesized that an interaction between PTB and hnRNP A1, which binds to a site in the 3'UTR, plays an important role in RNA replication (20, 29, 35). If this hypothesis is correct, the poor binding activity of PTB with the TRS region would result in a failure to mediate the formation of an RNP complex involving the 5'- and 3'-end fragments of the A59/SCoV-5'UTR chimeric genome (29). If so, the chimeric genome would not be able to synthesize minus-sense gRNA. Alternatively, the N protein and PTB might efficiently bind to the 5' ends of A59/SCoV-5'UTR/MHV-TRS and A59/SCoV-SL3 chimeric genomes due to a good fit with the TRS, including flanking sequences. This binding activity would enable 5'-to-3' complex formation and consequently allow the synthesis of minus-sense gRNA. However, they would be blocked at the leader-body joining step of subgenomic RNA synthesis, where a base-pairing scanning step is thought to regulate this event (41). A lack of sufficient complementary sequence domains would then be predicted to result in a failure to produce sgmRNA7s. Alternatively, differences in the structures of MHV and SCoV 5'UTRs and the various chimeras could have affected the translational efficiencies of the electroporated genomes and hence the levels of replicase proteins. In this instance, differences in the amounts of replicase proteins produced in cells electroporated with different chimeras would determine the particular RNA phenotype observed. We currently have no data on the effects (if any) that the different chimeric 5'UTRs might have on the translation of ORF1a and ORF1b, and thus, we cannot rule out this possibility. Further studies are needed to determine if either of these two hypotheses are correct.
In spite of considerable differences in sequence, the putative cis-acting structural elements are highly conserved and in some cases have been demonstrated to be functionally exchangeable among the group 2 coronaviruses. The inability of the complete SCoV 5'UTR to functionally replace the MHV 5'UTR suggests that recombination events between these two viruses that yield viable recombinants will be uncommon and typically will require two crossover events. However, the compatibility of putative cis-acting elements within the 5'UTRs and 3'UTRs from related coronaviruses suggests that with some additional changes (mutations), viral interspecies recombination could be facilitated. The functional studies reported here provide data that are critical to our understanding of both the phylogenetic relationship of SCoV to other group 2 coronaviruses and the natural evolution of coronaviruses.
We thank Lichun Li in the Department of Biochemistry and Biophysics for help in generating output from secondary structure prediction algorithms. We also thank Lindsay Patty for constructing the plasmid used to generate A59/nsp12-FS mutant genomes and the other members of the Leibowitz laboratory for their help and encouragement.
Published ahead of print on 18 August 2006. ![]()
Supplemental material for this article may be found at http://jvi.asm.org/. ![]()
Present address: Genome Damage and Stability Centre, University of Sussex, Falmer, Brighton, East Sussex BN1 9RQ, United Kingdom. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»